Bayer has confirmed its currency-adjusted forecast for full-year 2024. However, the negative impact from anticipated currency effects has increased based on the closing rates as of March 31, 2024. Applying the rates on that closing date instead of December 31, 2023, leads to a reduction in the forecast for EBITDA before special items from between EUR 10.4B and EUR 11B euros to between EUR 10.2B and EUR10.8B, for example. Sees core EPS at closing rates on March 31 EUR 4.80-EUR 5.20. Anticipates EBITDA before special items of EUR 10.7B-EUR 11.3B on a currency-adjusted basis. Sees free cash flow of EUR 2B-EUR 3B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Is BAYRY a Buy, Before Earnings?
- Bayer to present data from Kerendia trial program at Heart Failure 2024 Congress
- MOO ETF: Agriculture Stocks Are Inexpensive and Defensive
- Bayer, Google Cloud partner on AI-powered healthcare product for radiologists
- Bayer (BAYRY) Reveals Q2 Dividend: Here’s the Essential Information